CROSSJECT (EPA:ALCJ) | Finanzwire

Basculer en Français

11025	Companies
241658	Keywords
170134	Articles
130109	Press releases

Home
Companies
CROSSJECT

PRESS RELEASE

published on 05/20/2025 at 07:30, 1 year 3 months ago

CROSSJECT prepares for the launch of a capital increase with preferential subscription rights of around 5 million euros in preparation for commercial and production activities linked to EUA approval
CROSSJECT plans 5 million euros capital increase, may increase to 5.8 million euros, Gemmes Venture to guarantee 75% of initial amount, Heights Capital Management supports offer

Capital Increase Crossject Gemmes Venture Heights Capital Management EUA Approval
BRIEF

published on 05/07/2025 at 07:35, 1 year 4 months ago

CROSSJECT: Progress in the EUA authorization application for ZEPIZURE®

FDA USA ZEPIZURE® BARDA CHEMPACK
BRIEF

published on 03/27/2025 at 07:35, 1 year 5 months ago

CROSSJECT Publishes 2024 Financial Results

Financial Results Cash Position Partnerships FDA Filing ZEPIZURE®
PRESS RELEASE

published on 03/27/2025 at 07:30, 1 year 5 months ago

CROSSJECT reports financial results for 2024
CROSSJECT reports financial results for 2024 and progress in clinical and regulatory activities, recruitment of COO, and increased cash position. Key achievements and future plans outlined

Financial Results Cash Position Clinical Activities Crossject Regulatory Development
BRIEF

published on 03/25/2025 at 07:35, 1 year 5 months ago

Strategic partnership between CROSSJECT and ETON PHARMACEUTICALS

Eton Pharmaceuticals Crossject ZENEO® Hydrocortisone Adrenal Insufficiency
PRESS RELEASE

published on 03/25/2025 at 07:30, 1 year 5 months ago

CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program
CROSSJECT enhances collaboration with ETON PHARMACEUTICALS Inc. on ZENEO adrenal insufficiency program, introducing new hydrocortisone formulation for the hospital market

Eton Pharmaceuticals Crossject Hydrocortisone Adrenal Insufficiency ZENEO
BRIEF

published on 03/10/2025 at 14:22, 1 year 6 months ago

Crossject: Update on voting rights and shares as of January 31, 2025

Share Capital Voting Rights Actions Pharmaceutical Crossject
BRIEF

published on 02/12/2025 at 07:35, 1 year 7 months ago

Crossject Reappoints Key Members to Executive Board

Executive Board Crossject ZEPIZURE® Reappointment Needle-free Technology
PRESS RELEASE

published on 02/12/2025 at 07:30, 1 year 7 months ago

Crossject announces the reappointment of Patrick Alexandre and Isabelle Liebschutz as members of new, streamlined Executive Board
Crossject reappoints Patrick Alexandre and Isabelle Liebschutz to its Executive Board, focusing on final stages of ZEPIZURE registration with the FDA

Executive Board Crossject Patrick Alexandre Isabelle Liebschutz ZEPIZURE Registration
BRIEF

published on 02/06/2025 at 07:35, 1 year 7 months ago

Modification of Convertible Bonds by Crossject

Convertible Bonds Funding Crossject ZEPIZURE Heights Capital

Accesswire

Published on 09/19/2026 at 00:55, 9 hours 19 minutes ago

Gossan Resources Announces Changes to Board and Management
Published on 09/18/2026 at 23:50, 10 hours 24 minutes ago

Mako Mining Announces Equity Incentive Grants
Published on 09/18/2026 at 22:00, 12 hours 14 minutes ago

Silver Tiger Announces Results of Annual and Special Meeting
Published on 09/18/2026 at 20:35, 13 hours 39 minutes ago

Only 11% of Marketers Expect Google Search to Be Their Customers' Main Starting Point in Two Years
Published on 09/18/2026 at 14:30, 19 hours 44 minutes ago

AIAI Holdings to Obtain a Controlling Position in Messier 42 Marketing Agreement

View all ACCESSWIRE

EQS Group

Published on 09/19/2026 at 07:30, 2 hours 44 minutes ago

Hong Kong sets out initiatives to secure long-term development of pillar industries
Published on 09/18/2026 at 18:45, 15 hours 29 minutes ago

Holding(s) in Company
Published on 09/18/2026 at 18:44, 15 hours 30 minutes ago

EQS-Adhoc: Enapter AG announces preliminary, unaudited figures for the first half of 2026 and restructures its US sales operations – one-off expense of EUR 17 million
Published on 09/18/2026 at 18:13, 16 hours 1 minute ago

Multi Units Luxembourg: NOTICE TO SHAREHOLDERS
Published on 09/18/2026 at 18:09, 16 hours 4 minutes ago

Multi Units Luxembourg: NOTICE TO SHAREHOLDERS

Les Echos

Published on 09/18/2026 at 18:34, 15 hours 40 minutes ago

Disclosure of transactions in own shares from September 14 to September 18, 2026
Published on 09/18/2026 at 17:45, 16 hours 29 minutes ago

Press Release_Carrefour Bond_September 2026
Published on 09/18/2026 at 17:45, 16 hours 29 minutes ago

Share buyback for cancellation
Published on 09/17/2026 at 17:40, 1 day 16 hours ago

Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
Published on 09/16/2026 at 20:46, 2 days 13 hours ago

LNA SANTE : 2026 First Half Results

View all LES ECHOS COMFI WIRE